Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2025)

Amylyx Pharmaceuticals has reported Other Non Operating Income over the past 5 years, most recently at $362000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 130.57% year-over-year to $362000.0; the TTM value through Dec 2025 reached -$699000.0, up 42.42%, while the annual FY2025 figure was -$700000.0, 42.34% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $362000.0 at Amylyx Pharmaceuticals, up from -$180000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $362000.0 in Q4 2025 and troughed at -$747000.0 in Q1 2024.
  • A 5-year average of -$158750.0 and a median of -$111000.0 in 2023 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 187.67% in 2022 and later crashed 1278.95% in 2023.
  • Year by year, Other Non Operating Income stood at -$59000.0 in 2021, then tumbled by 1067.8% to -$689000.0 in 2022, then soared by 124.82% to $171000.0 in 2023, then decreased by 8.19% to $157000.0 in 2024, then skyrocketed by 130.57% to $362000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for AMLX at $362000.0 in Q4 2025, -$180000.0 in Q3 2025, and -$546000.0 in Q2 2025.